Researchers disclosed SPVN06, a mutation‑agnostic gene therapy approach for rod‑cone dystrophies that aims to preserve photoreceptors across genetic subtypes. Preclinical and early safety data indicate a favorable profile and efficacy signal in models, positioning SPVN06 as a potential broad‑spectrum option for inherited retinal degeneration. The approach targets shared pathways across genotypes rather than correcting individual mutations; mutation‑independent strategies aim to simplify development for genetically heterogeneous retinal diseases but still need controlled clinical assessments to establish durability and functional vision benefit.